IGKV1D-22 and atherosclerosis: Moreover, controlling glucose levels in diabetic mice with a sodium glucose co-transporter 2 inhibitor (SGLT2i) reduces circulating S100A8/A9 and prevents both diabetes-induced myelopoiesis and atherosclerosis.